Sun,
Jefferies stated in a note that analyst Dr. alopecia areata during the call with a Jefferies US analyst regarding the Concerta Pharma acquisition and its recent acquisition by Sun Pharma.
They talked about Deuruxolitinib’s potential ramp-up, profitability, drug use, and IP issues. In terms of profitability, Maury stated that the cost of goods sold (COGS) for Deuruxolitinib could be 6-12% of sales price, that marketing expenses could range from $50 million to $100 million (if the product reaches sales of less than USD 500 million), and that the current open-label study and initial OPEX for the product could require annual costs ranging from $20 million to $40 million (we used USD50 million cost for the NPV calculation for Deuruxolitinib). model has been prepared),” read the note. With a target price of Rs, the brokerage maintains a buy rating on Sun Pharma shares. 1,200 each.
Drug significant Sun Pharma finished the obtaining of US-based Show Drugs recently subsequent to consenting to an arrangement to gain the firm in January in a $576 million arrangement.
The brokerage pointed out that Concerta Pharma’s clinical trials indicated that it would compete with competing products from Eli Lilly and Pfizer, and that Phase III data were not available, explaining why Sun got a good deal on Concerta. It was affirmed from Show Pharma had a market capitalization of under $1 billion not long before the end of exchanging.
“Big Pharma dropped the company’s best-in-class product probably due to IP issues surrounding the product, and some of them, such as Lilly, Pfizer, and BMS, have their own program for Alopecia Areata. Additionally, Concert Pharma required a partnership because it lacked a cash runway beyond 2023. Sun Pharma may have been able to get a good deal for the Concert acquisition thanks to the acquisition’s low competitive intensity and Concert’s decreasing cash reserves. o2help does not share the opinions or recommendations expressed above.
